Drug Substance/HPAPI

Maurits Janssen, Ph.D.

Maurits Janssen serves as Executive Director, Strategic Business Development, for the Small Molecules Division at Lonza and is located in Basel, Switzerland. Maurits has more than 25 years of experience in the chemical and pharmaceutical industries and has worked on a broad portfolio of technologies, focusing on the custom development and manufacturing of active pharmaceutical ingredients (CDMO). His expertise includes chemical and biological custom development & manufacturing from early-stage to late-phase & commercial under current Good Manufacturing Practice (cGMP) conditions. Experience includes highly potent active pharmaceutical ingredients (HPAPIs), cytotoxic compounds, peptides and conjugates, as well as a variety of products produced using mammalian or microbial platform technologies. In addition to Lonza, he has worked for Siegfried, RohnerChem, and Sigma Aldrich, holding positions of increasing responsibility in management consulting, marketing and sales, and research and development functions. Maurits earned his Ph.D. in Organic Chemistry from Utrecht University, The Netherlands.

Content by this expert

Recently published by Maurits

Whitepaper/Executive Summary

Maurits Janssen, Ph.D.

Recently published by Maurits

Requirements for Fully Integrated Offerings in a HPAPI and Cytotoxic Environment

The Rise of HPAPI Molecules - Trends in Highly Potent API Manufacturing

JAPANESE - Requirements for fully-integrated service-offerings in a HPAPI and cytotoxic environment

Best Practices for Highly Potent API (HPAPI) Development and Manufacturing